Drug profile · INN
glasdegib maleate
DAURISMO
glasdegib maleate (DAURISMO) is a smoothened homolog antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — glasdegib maleate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
glasdegib maleate (DAURISMO) is a smoothened homolog antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Smoothened homolog antagonist
Primary target: Protein smoothened
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is glasdegib maleate?
glasdegib maleate (DAURISMO) is a smoothened homolog antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for glasdegib maleate?
DAURISMO is a marketed brand name for glasdegib maleate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of glasdegib maleate?
glasdegib maleate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.